Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hodgkin
Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H1 2019”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H1
2019 provides comprehensive information on the therapeutics
under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
(Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
(Oncology) pipeline guide also reviews key players involved in
therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
and features dormant and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed,
Preclinical and Unknown stages are 2, 2, 43, 29, 1, 13 and 1
respectively. Similarly, the Universities portfolio in Phase II, Phase
I, Preclinical and Discovery stages comprises 6, 3, 2 and 1 molecules,
respectively.

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide
helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to
create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
• The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma
  (B-Cell Hodgkin Lymphoma) (Oncology) by companies and
  universities/research institutes based on information derived from
  company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise product description, descriptive licensing and
  collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hodgkin Lymphoma
  (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics and enlists all
  their major and minor projects.
• The pipeline guide evaluates Hodgkin Lymphoma (B-Cell Hodgkin
  Lymphoma) (Oncology) therapeutics based on mechanism of action (MoA),
  drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline depth
  and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Key Topics Covered

1. Introduction
2. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Overview
3. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Development
4. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Assessment
5. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Companies Involved in
   Therapeutics Development
6. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drug Profiles
7. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects
8. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products
9. Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Product Development
   Milestones
10. Appendix

Companies Mentioned

• A. Menarini Industrie Farmaceutiche Riunite Srl
• AbbVie Inc
• Actinium Pharmaceuticals Inc
• ADC Therapeutics SA
• Aduro BioTech Inc
• Affimed GmbH
• AlfaSigma SpA
• Alissa Pharma
• Anhui Anke Biotechnology (Group) Co Ltd
• Apollomics Inc
• Astellas Pharma Inc
• AstraZeneca Plc
• Aurigene Discovery Technologies Ltd
• BeiGene Ltd
• Biohaven Pharmaceutical Holding Company Ltd
• Bristol-Myers Squibb Co
• Carrick Therapeutics Ltd
• Celgene Corp
• Cell Medica Ltd
• Celldex Therapeutics Inc
• Cellectar Biosciences Inc
• Cellectis SA
• Celleron Therapeutics Ltd
• Cellestia Biotech AG
• Cellular Biomedicine Group Inc
• Celularity Inc
• Checkpoint Therapeutics Inc
• Chipscreen Biosciences Ltd
• Constellation Pharmaceuticals Inc
• Curis Inc
• Eureka Therapeutics Inc
• F. Hoffmann-La Roche Ltd
• Faron Pharmaceuticals Oy
• FLX Bio Inc
• Harbin Gloria Pharmaceuticals Co Ltd
• Immunomedics Inc
• Incyte Corp
• Inhibrx LP
• Jiangsu Hengrui Medicine Co Ltd
• Kiromic Inc
• Kite Pharma Inc
• MedImmune LLC
• Merck & Co Inc
• Merck KGaA
• Miltenyi Biotec GmbH
• Molecular Templates Inc
• NantKwest Inc
• NBE-Therapeutics AG
• Recursion Pharmaceuticals Inc
• Regeneron Pharmaceuticals Inc
• and many more…

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5e6axt

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Lymphoma
Drugs